IP Verse

Means And Methods For Treating Dlbcl - EP3018145

The patent EP3018145 was granted to Amgen Research Munich on Apr 4, 2018. The application was originally filed on Oct 27, 2011 under application number EP15195076A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3018145

AMGEN RESEARCH MUNICH
Application Number
EP15195076A
Filing Date
Oct 27, 2011
Status
Granted And Under Opposition
Mar 2, 2018
Grant Date
Apr 4, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AFFIMEDDec 21, 2018SCHMITZWITHDRAWN

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0623679
DESCRIPTIONWO2004106381
DESCRIPTIONWO2005052004
DESCRIPTIONWO2007068354
DESCRIPTIONWO2008119565
DESCRIPTIONWO9954440
OPPOSITIONUS2008138336
OPPOSITIONUS2009285808
OPPOSITIONWO2007068354
SEARCHWO2007068354
SEARCHWO2011051307

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALIZADEH ET AL., NATURE, (2000), vol. 403, pages 503 - 511-
DESCRIPTION- ARMITAGE, BLOOD, (2007), vol. 110, no. 1, pages 29 - 36-
DESCRIPTION- ARTHRITIS RHEUM., (200602), vol. 54, no. 2, pages 613 - 20-
DESCRIPTION- BAEK ET AL., METHODS ENZYMOL., (2003), vol. 362, pages 240 - 9-
DESCRIPTION- BERGE, S. M. ET AL., J. PHARM. SCI., (1977), vol. 66, pages 1 - 19-
DESCRIPTION- CHESON ET AL., J. CLIN. ONCOL., (2007), vol. 25, no. 5, pages 579 - 586-
DESCRIPTION- CRICK, J MOL BIOL, vol. 19, (1966), pages 548 - 55, URL: http://en.wikipedia.org/wiki/Wobb!e__Hypothesis-
DESCRIPTION- DUBOIS, ARCH INT MED, (1916), vol. 17, pages 863 - 871-
DESCRIPTION- GEHAN, CANCER CHEMOTHER REP, (1970), vol. 54, pages 225 - 35-
DESCRIPTION- HAYCOCK, THE JOURNAL OF PEDIATRICS, (1978), vol. 93, no. 1, pages 62 - 66-
DESCRIPTION- MOLNAR; LAPIN; GOOTHUIS, NEUROONCOL., (1995), vol. 25, no. 1, pages 19 - 28-
DESCRIPTION- NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, pages 443 - 453-
DESCRIPTION- NIGAVEKAR ET AL., PHARM RES., (2004), vol. 21, no. 3, pages 476 - 83-
DESCRIPTION- SHIPP ET AL., NAT MED, (2002), vol. 8, pages 68 - 74-
DESCRIPTION- SMITH; WATERMAN, ADV. APPL. MATH, (1981), vol. 2, pages 482 - 489-
OPPOSITION- COIFFIER et al., "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study", Blood, (19980000), vol. 92, no. 6, pages 1927 - 1932, XP055541896-
OPPOSITION- MATTHIAS KLINGER, "Wirkmechanismus des bispezifischen anti- CD 19 x ant- CD 3 BiTE- Antikörpers MT 103 in Patienten mit rezidivem indolenten B-Zell-Non-Hodgkin- Lymphom", Doctoral Thesis University of Tübingen, (20090926), URL: https://publikationen.uni-tuebingen.de/xmlui/bitstream/handle/10900/43908/pdf/Dissertation_Matthias_Klinger.pdf?sequence=1, XP055541894-
OPPOSITION- RALF BARGOU et al., "Supporting Online Material for '' Tumor Regression by Very Low Doses of a T Cell -Engaging Antibody", Science, vol. 321, (20080815), page 974, URL: www.sciencemae.ore/cgi/content/full/321/5891/974/DCl, XP055500980
OPPOSITION- BARGOU R et al., "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody", Science, (20080815), vol. 321, no. 5891, pages 974 - 977, XP002615656
SEARCH- SOPHIE DUPIRE ET AL, "Targeted treatment and new agents in diffuse large B cell lymphoma", INTERNATIONAL JOURNAL OF HEMATOLOGY, (20100701), vol. 92, no. 1, doi:10.1007/s12185-010-0609-6, ISSN 0925-5710, pages 12 - 24, XP055023306 [I] 1-15 * abstract * * page 12, column l, paragraph l - column r, paragraph 2 * * page 21, column l, paragraph 2 * * table 1 *
SEARCH- NG ET AL, "Diffuse Large B-Cell Lymphoma", SEMINARS IN RADIATION ONCOLOGY, SAUNDERS, PHILADELPHIA, PA, US, (20070623), vol. 17, no. 3, doi:10.1016/J.SEMRADONC.2007.02.002, ISSN 1053-4296, pages 169 - 175, XP022128313 [A] 1-15 * the whole document *
SEARCH- BARGOU RALF ET AL, "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, (20080815), vol. 321, no. 5891, doi:10.1126/SCIENCE.1158545, ISSN 0036-8075, pages 974 - 977, XP002615656 [I] 1-15 * the whole document *
SEARCH- QUINTÁS-CARDAMA ALFONSO ET AL, "Investigational immunotherapeutics for B-cell malignancies.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 10 FEB 2010 LNKD- PUBMED:20048186, (20100210), vol. 28, no. 5, ISSN 1527-7755, pages 884 - 892, XP009157966 [I] 1-15 * page 884, column l, paragraph 1 - column r, paragraph 2 * * page 888, column l, paragraph l * * page 889, column l, paragraph 2 - column r, paragraph 1 *
SEARCH- WILSON WYNDHAM H ET AL, "Novel disease targets and management approaches for diffuse large B-cell lymphoma", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, (20100801), vol. 51, no. supplement 1, doi:10.3109/10428194.2010.500045, ISSN 1042-8194, pages 1 - 10, XP008135253 [I] 1-15 * abstract * * page 1, column l, paragraph 1 - page 2, column l, paragraph 2 * * page 7, column l, paragraph 2 * * page 8, column r, paragraph l * * table II *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents